Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan

Summary. Cytomegalovirus (CMV) infection in 28 adult patients after cord blood transplantation (CBT) from unrelated donors was compared with that after bone marrow transplantation from HLA (human leucocyte antigen)‐matched related (R‐BMT) and unrelated (U‐BMT) donors. Positive CMV antigenaemia was seen in 19 (79%) of 24 CMV‐seropositive patients at a median of 42 d (range 29–85 d) after CBT, but in zero of four CMV‐seronegative patients. This did not differ significantly from values observed after R‐BMT and U‐BMT (66%, P = 0·22, and 60%, P = 0·15 respectively). Based on the antigenaemia results, 16 patients (67%) received pre‐emptive ganciclovir therapy from a median of 47 d (range 36–67 d) after CBT. This proportion was higher than that observed after R‐BMT (28%, P = 0·0048), but did not differ from that after U‐BMT (50%, P = 0·21). In addition, the probability of requiring more than two courses of ganciclovir therapy after CBT (21%) was higher than after R‐BMT and U‐BMT (0%, P = 0·015 and 0·039 respectively). One patient (5%) developed CMV disease after U‐BMT, whereas no patients developed CMV disease after CBT or R‐BMT. The CMV serostatus, use of a steroid and HLA disparity affected the probability of requiring ganciclovir therapy after CBT (P = 0·024, 0·032 and 0·017 respectively). These results suggest that recovery of CMV‐specific immunity after CBT is delayed when compared with BMT.

[1]  J. Zaia,et al.  Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants , 2002, Transplantation.

[2]  S. Asano,et al.  A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukaemia in complete remission , 2002, British journal of haematology.

[3]  H. Einsele,et al.  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. , 2002, Blood.

[4]  S. Asano,et al.  Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome‐related secondary acute myeloid leukaemia , 2001, British journal of haematology.

[5]  J. Wagner,et al.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. , 2001, The New England journal of medicine.

[6]  A. Zander,et al.  Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. , 2001, Blood.

[7]  S. Mineishi,et al.  Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan , 2001, Bone Marrow Transplantation.

[8]  H. Einsele,et al.  Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. , 2001, Blood.

[9]  D. Heilman,et al.  Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. , 2000, Blood.

[10]  K. Adal,et al.  A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy , 2000, Bone Marrow Transplantation.

[11]  M. Boeckh,et al.  Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. , 1999, Blood.

[12]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[13]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[14]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. , 1997, The New England journal of medicine.

[15]  M. Boeckh,et al.  Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.

[16]  K. Atkinson,et al.  Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. , 1995, Bone marrow transplantation.

[17]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[18]  S. Forman,et al.  Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? [see comments] , 1994 .

[19]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[20]  S. Forman,et al.  Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? , 1994, Blood.

[21]  K. Ikebuchi,et al.  Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. , 1994, Bone marrow transplantation.

[22]  D. Deluca,et al.  Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.